185 related articles for article (PubMed ID: 37436074)
1. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
[TBL] [Abstract][Full Text] [Related]
2. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
Ma X; Ren H; Zhang Y; Wang B; Ma H
Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
[TBL] [Abstract][Full Text] [Related]
3. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
4. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal protein L22-like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway.
Yi X; Zhang C; Liu B; Gao G; Tang Y; Lu Y; Pan Z; Wang G; Feng W
J Cell Mol Med; 2023 Feb; 27(3):403-411. PubMed ID: 36625246
[TBL] [Abstract][Full Text] [Related]
6. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
[TBL] [Abstract][Full Text] [Related]
7. EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
Fan HT; Shi YY; Lin Y; Yang XP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7808-7815. PubMed ID: 31599405
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
Ma T; Chen H; Wang P; Yang N; Bao J
Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
[No Abstract] [Full Text] [Related]
9. Hydroxysafflor Yellow A Promotes HaCaT Cell Proliferation and Migration by Regulating HBEGF/EGFR and PI3K/AKT Pathways and Circ_0084443.
Zhang Y; Xiao YW; Ma JX; Wang AX
Chin J Integr Med; 2024 Mar; 30(3):213-221. PubMed ID: 37688744
[TBL] [Abstract][Full Text] [Related]
10. Analyzing roles of small nucleolar RNA host gene 25 from clinical, molecular target and tumor formation in prostate cancer.
Liu Z; Ke S; Wang Q; Gu X; Zhai G; Shao H; He M; Guo J
Exp Cell Res; 2023 Aug; 429(2):113686. PubMed ID: 37307941
[TBL] [Abstract][Full Text] [Related]
11. Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway.
Sun J; Zhao H; Shen C; Li S; Zhang W; Ma J; Li Z; Zhang M; Yang J
Stem Cell Res Ther; 2022 Jun; 13(1):269. PubMed ID: 35729652
[TBL] [Abstract][Full Text] [Related]
12. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
14. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
15. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways.
Gu Z; You Z; Yang Y; Ding R; Wang M; Pu J; Chen J
Bioengineered; 2021 Dec; 12(1):4719-4735. PubMed ID: 34338146
[TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.
Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X
Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-218-5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway.
Han S; Chen Y; Gao Y; Sun B; Kong Y
Exp Eye Res; 2019 Jan; 178():37-45. PubMed ID: 30243568
[TBL] [Abstract][Full Text] [Related]
19. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
Xu S; Ge J; Zhang Z; Zhou W
Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
[TBL] [Abstract][Full Text] [Related]
20. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
